Victoria Clendaniel is a research associate at Verve Therapeutics. Most recently, she worked as a research assistant at Beth Israel Deaconess Medical Center (BIDMC), where she researched HDAC3 inhibition as a therapeutic treatment for experimental stroke. Ms. Clendaniel gained experience as an undergraduate researcher at BIDMC, where she contributed to research in Alzheimer’s disease, dementia and Parkinson’s disease. She received her B.S. in biology, with a concentration in health sciences, from Emmanuel College.